In this review we focus on the delivery of the clinical data required to advance such drug-diagnostic combination development programmes and ultimately satisfy regulators and payors of the value of contemporaneous changes in diagnostic and treatment practice.
This study aims at identifying and applying suitable methods for a cost benefit analysis from the perspective of the payor for health services.
In multivariate analyses, use of NPs was associated with age, sex, payor and number of chronic conditions, and use of NVNMDS was associated with age and race.
From the standpoint of a payor, a similar amount of money could be used to treat strokes that result from non-use of warfarin, or to provide an incentive system like this, which reduces the rate of strokes, which is clearly a better outcome for the patients.
Refusal of payors to reimburse clinical genomes and exomes is also a great hindrance to broad utilization.
It is likely that our model of workforce supply is somewhat simplified, as we are only able to adjust crudely for potential confounding factors such as insurance payor and modality of physician reimbursement (private practice or HMO versus other types of employment).
When analyzed by payor the majority of the increased usage in 1997 was by uninsured and Medicaid children.
By pooling their resources, physicians can spread the costs associated with the analysis of payor contracts, and develop appropriate counteroffers that can benefit patient, physicians, and payors.
This situation may impact Medicare, the major source of health care funding for the elderly and the largest single payor for these services [ 3, 4].
This set of integrated economics allows payors to estimate the burden of uncured chronic HCV in their population as well as contrast the pharmacy and medical costs for 14 years between three therapeutic scenarios.
